<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04392557</url>
  </required_header>
  <id_info>
    <org_study_id>Inflammation-DM2</org_study_id>
    <nct_id>NCT04392557</nct_id>
  </id_info>
  <brief_title>Anti-inflammatory Status in DM2 Treated Patients</brief_title>
  <acronym>INF-DM2-Ther</acronym>
  <official_title>Comparison of Anti-inflammatory Status Linked to Atherosclerosis Formation/Progression Among Diabetes Mellitus Type 2 Patients Under Combined Pharmacological Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Catanzaro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Catanzaro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes mellitus Type 2 (DMT2) - a progressive insulin secretory defect on the background of
      insulin resistance - is one of the major risk factors for atherosclerosis, an inflammatory
      disease of the arterial wall, in which leukocytes and oxidized lipoproteins accumulate
      leading to formation of fatty streaks and atherosclerotic plaques. Atherosclerosis accounts
      for more than 600,000 deaths annually in the U.S. mainly due to acute myocardial infarction
      and stroke. Pharmacological therapy of DMT2 includes several drugs used as monotherapy,
      although combination therapy between metfomin plus thiazolidinediones (TZD) and/or
      dipeptidyl-peptidase 4 inhibitors (DPP4I) plus TDZ, may delay atherosclerosis progression
      even if the molecular mechanisms are not clear. Even if normoglycemia is achieved, DMT2
      patients still displayed a higher risk for developing atherosclerosis suggesting that other
      mechanisms of the inflammatory status are involved
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes mellitus Type 2 (DMT2) - a progressive insulin secretory defect on the background of
      insulin resistance - is one of the major risk factors for atherosclerosis, an inflammatory
      disease of the arterial wall, in which leukocytes and oxidized lipoproteins accumulate
      leading to formation of fatty streaks and atherosclerotic plaques. Atherosclerosis accounts
      for more than 600,000 deaths annually in the U.S. mainly due to acute myocardial infarction
      and stroke. Pharmacological therapy of DMT2 includes several drugs used as monotherapy,
      although combination therapy between metfomin plus thiazolidinediones (TZD) and/or
      dipeptidyl-peptidase 4 inhibitors (DPP4I) plus TDZ, may delay atherosclerosis progression
      even if the molecular mechanisms are not clear . Even if normoglycemia is achieved, DMT2
      patients still displayed a higher risk for developing atherosclerosis suggesting that other
      mechanisms of the inflammatory status are involved
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>single center single blind study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>inflammatory miRNA</measure>
    <time_frame>12 months</time_frame>
    <description>Change from Baseline at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>side effects</measure>
    <time_frame>12 months</time_frame>
    <description>statistically significant difference (P&lt;0.05) in the development of side effects between the groups, recorded using the Naranjo adverse drug reactions scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>body weight</measure>
    <time_frame>12 months</time_frame>
    <description>effects of each treatment on body mass index (kg/m^2) (as indirect indexes of systemic inflammation and visceral adiposity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist values</measure>
    <time_frame>12 months</time_frame>
    <description>effects of each treatment on waist values (cm) (as indirect indexes of systemic inflammation and visceral adiposity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>drug interaction</measure>
    <time_frame>12 months</time_frame>
    <description>statistically significant difference (P&lt;0.05) in the development of drug-drug interactions, recorded using the DIPS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>12 months</time_frame>
    <description>effects of each treatment on fasting blood glucose (mg/dL) (as indexes of glucose metabolism);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c levels</measure>
    <time_frame>12 months</time_frame>
    <description>effects of each treatment on HbA1c levels (percent) (as indexes of glucose metabolism);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver function</measure>
    <time_frame>12 months</time_frame>
    <description>alanine aminotransferase, aspartate aminotransferase, gamma glutamyl-transpeptidase levels, and total bilirubin levels (expressed as mg/dL) (as indexes of liver function).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cell count</measure>
    <time_frame>12 months</time_frame>
    <description>effects of each treatment on white blood cell count expressed as cell/mm3 (as direct index of systemic inflammation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid metabolism/atheroscelorisis</measure>
    <time_frame>12 months</time_frame>
    <description>total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides levels (expressed as mg/dL) (as direct indexes of lipid metabolism and atheroscelorisis).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>metformin/alogliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin/alogliptin (850 mg/12.5 mg or 1000 mg/12.5 mg every 12 hours) for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin/pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin/pioglitazone (850 mg/15 mg every 12 hours) for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>triple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin/pioglitazone (850 mg/15 mg every 12 hours)+alogliptin (12.5 mg every 12 hours) for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin / alogliptin Oral Product</intervention_name>
    <description>850 or 1000 mg/ 12.5 mg every 12 hours for 12 months</description>
    <arm_group_label>metformin/alogliptin</arm_group_label>
    <arm_group_label>triple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin / Pioglitazone Pill</intervention_name>
    <description>(850 mg/15 mg every 12 hours) for 12 months</description>
    <arm_group_label>metformin/pioglitazone</arm_group_label>
    <arm_group_label>triple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triple therapy</intervention_name>
    <description>Metformin / Alogliptin/ Pioglitazone</description>
    <arm_group_label>triple therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DMT2 patients were enrolled in presence of

               1. Age &gt;35 and &lt;75 years old

               2. Uncontrolled diabetes during treatment (glycosylated hemoglobin (HbA1c) &gt; 75
                  mmol/mol )

               3. Combined therapy at least by 6 months.

        Exclusion Criteria:

          1. HbA1c &lt; 75 mmol/mol (9%);

          2. History of drug abuse or alcohol abuse, averaging more than 30 gm/day (3 drinks per
             day) in the previous 10 years, or history of alcohol intake averaging greater than 10
             gm/day (1 drink per day: 7 drinks per week) in the previous one year;

          3. Estimated glomerular filtration rate (GFR) &lt;30 ml/min (according to MDRD formula)

          4. .Liver Failure

          5. Recent history of Heart stroke, systemic infections, dehydration, lactic acidosis

          6. Heart failure (NYHA I - IV)

          7. Active bladder cancer or history of bladder cancer

          8. macroscopic haematuria of unidentified nature

          9. hypersensitivity to drug used (metformin, alogliptin, pioglitazone)

         10. breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Azienda Sanitaria Provinciale</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Antonio Guerra, MD</last_name>
      <phone>3398199190</phone>
      <email>guerra.antonio@simg.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Scuteri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giacomo Leuzzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe Giuliano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Catanzaro</investigator_affiliation>
    <investigator_full_name>Luca Gallelli</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Alogliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

